American Society of Hematology Annual Meeting & Exposition (ASH) | Conference

At 24 weeks, patients with myelofibrosis transfused with serum ferritin and receiving momelotinib experienced a treatment response.

Investigators believe that storing red blood cells in a hypoxic state could reduce the development of vaso-occlusion flowing transfusion.

CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Using the International Prognostic Scoring System (IPSS) score and JAK2 mutation status, thrombosis risk could potentially be identified for patients with primary myelofibrosis.

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Data from a retrospective head-to-head analysis of pacritinib vs ruxolitinib showed that the former was more favorable in terms of symptom response for patients with myelofibrosis and thrombocytopenia.

Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.